Company news

Actinogen Medical Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

XanaMIA Part A trial achieves target enrolment

November 28, 2021

Strategic Update & Capital Raising Investor Presentation

November 24, 2021

Program Expansion & Capital Raising

November 24, 2021

ACW announces open IND for Phase 2 Fragile X trial & LOI

November 8, 2021

R&D Tax Incentive Rebate received of A$1.435 million

October 12, 2021

Actinogen Medical FY21 Results- Progressing the Pipeline

August 30, 2021

Actinogen completes global patent family grant

August 22, 2021

First Patient Enrolled in XanaMIA trial

July 14, 2021

Actinogen receives positive Pre-IND FDA advice for FXS

June 23, 2021

Clinical progress for XanaMIA trial

June 20, 2021

Actinogen Ethics Committee approval for XanaMIA study

June 1, 2021

Response to ASX Price Query

May 24, 2021

Strategic Update & Teleconference Call Notification

April 20, 2021

Actinogen CEO assumes Managing Director position

March 23, 2021

Actinogen appoints Dr Steven Gourlay as CEO

March 14, 2021

ACW raises an addtional $3.55m under a Shortfall Placement

February 10, 2021

Resignation of Dr Bill Ketelbey as Chief Executive Officer

February 8, 2021

FDA Grants ACW Rare Paediatric Disease Designation in FXS

February 4, 2021

Completion of Entitlement Offer

November 12, 2020

Actinogen files new patent applications

November 8, 2020

FDA IND Update

November 3, 2020

ACW to initiate XanaFX clinical trial in Fragile X syndrome

November 1, 2020

R&D Tax Incentive Rebate received of A$2.9 million

October 26, 2020

Offer Booklet

October 23, 2020

Actinogen Presentation & Planned Conference Call

October 14, 2020

Proposed issue of Securities - ACW

October 14, 2020

ACW announces two clinical trials & launches capital raising

October 14, 2020

Appendix 4E & Annual Report

August 26, 2020

Market Update COVID-19

March 25, 2020

December 2019 Quarterly Update

January 27, 2020

ACW 2019 AGM Chairman's Address

November 24, 2019

R&D Tax Incentive rebate received of $4.58 million

October 24, 2019

September 2019 Quarterly Update

October 23, 2019

Cognitive improvement demonstrated with Xanamem

October 1, 2019

June 2019 Quarterly Update

July 29, 2019

Xanamen Clinical Development & Investor Update

June 25, 2019

XanaHES Trial to Continue

May 28, 2019

Phase II Alzheimers Disease Trial - results

May 7, 2019

March 2019 Quarterly Update

April 23, 2019

New Clinical Development Opportunities for Xanamem

April 9, 2019

DSMB again reaffirms XanADu trial to continue without change

March 25, 2019

1st participant dosed in important new Xanamem study-XanaHES

February 10, 2019

December 2018 Quarterly Update

January 28, 2019

Final patient enrolled in landmark Alzheimers trial-XanADu

November 25, 2018

September 2018 Quarterly Update

October 30, 2018

Recruitment to close for important Alzheimers trial-XanADu

October 21, 2018

R&D Tax Rebate Received Totalling $3.15 Million

October 9, 2018

Appendix 4E & Financial Statements

August 29, 2018

DSMB reaffirms that XanADu continue without change

August 22, 2018

XanADu Patient Enrolment Advancing Towards Completion

August 14, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 88 decks. Every deck is listed under its year.